GO:0060290 transdifferentiation: Cellular Reprogramming, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060290 transdifferentiation is the direct conversion of one differentiated cell type into another without cell division or reversion to a stem-cell-like state.
• It is a fundamental biological process observed in development, tissue regeneration, and disease, including skeletal development and atherosclerosis.
• Key molecular drivers include transcription factors, epigenetic modifiers, and signaling pathways that remodel cell identity.
• Transdifferentiation is implicated in human diseases such as diabetes, atherosclerosis, glioblastoma, and pulmonary fibrosis.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of transdifferentiation regulators.
• Small molecules and chemical reprogramming can induce transdifferentiation, offering therapeutic opportunities.
Description
Transdifferentiation, defined by the Gene Ontology term GO:0060290, is the conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate. This process challenges the classical view that cell fate is irreversibly fixed and has broad implications for developmental biology, regenerative medicine, and disease pathogenesis. Unlike dedifferentiation followed by redifferentiation, transdifferentiation occurs directly, often through coordinated changes in transcription factor networks and epigenetic landscapes. Researchers study transdifferentiation to understand how cell identity is maintained and can be manipulated, with potential applications in tissue repair and cancer therapy. The process is observed in various physiological and pathological contexts, including skeletal development, smooth muscle cell plasticity in atherosclerosis, and cholangiocyte-to-hepatocyte conversion in liver disease. Understanding the molecular mechanisms of transdifferentiation is essential for developing targeted interventions that can promote desired cell fate changes or prevent pathological ones.
transdifferentiation At A Glance
| GO ID | GO:0060290 |
|---|---|
| GO term | transdifferentiation |
| Ontology | biological_process |
| Synonym | None |
| Definition | The conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate. |
| Major function | Direct cell fate conversion without dedifferentiation |
| Related processes | Cellular reprogramming, lineage switching, metaplasia |
| Disease relevance | Diabetes, atherosclerosis, glioblastoma, pulmonary fibrosis, liver disease |
What Is GO:0060290?
According to the Gene Ontology, transdifferentiation (GO:0060290) is the conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate. In other words, a specialized cell directly changes into a different specialized cell type, bypassing intermediate pluripotent or progenitor states. This definition distinguishes transdifferentiation from dedifferentiation (reversion to a less differentiated state) and from differentiation from stem cells. The process involves coordinated changes in gene expression, epigenetic modifications, and cellular morphology, often driven by transcription factors and signaling cues.
Why Is transdifferentiation Important in Cell Biology?
Transdifferentiation is critically important because it represents a mechanism by which cells can change identity in response to physiological or pathological cues, contributing to tissue regeneration, organ development, and disease progression. Understanding transdifferentiation can reveal new therapeutic strategies for regenerating damaged tissues, such as converting fibroblasts into cardiomyocytes or hepatocytes, and for preventing pathological cell fate changes that drive cancer and fibrosis. Moreover, transdifferentiation is a key process in the progression of diseases like type 2 diabetes, where pancreatic beta cells may transdifferentiate into other endocrine cell types, and in atherosclerosis, where smooth muscle cells transdifferentiate into macrophage-like cells.
• Provides a mechanism for direct cell fate conversion without stem cell intermediates.
• Plays a role in normal development, including skeletal and organ formation.
• Contributes to tissue regeneration and repair in response to injury.
• Is implicated in the pathogenesis of type 2 diabetes through beta-cell transdifferentiation.
• Drives smooth muscle cell transdifferentiation in atherosclerosis, affecting plaque stability.
• Involved in cancer progression, including glioblastoma stem cell transdifferentiation.
• Underlies cholangiocyte-to-hepatocyte conversion in liver disease.
• Can be induced by small molecules for regenerative therapies.
• Serves as a model for studying epigenetic and transcriptional control of cell identity.
• Offers targets for CRISPR-based interventions to modulate cell fate.
What Happens During transdifferentiation?
Initiation and Fate Conversion
In simple terms: A specialized cell receives signals that start the process of changing into a different cell type.
Transdifferentiation begins when a differentiated cell receives intrinsic or extrinsic signals that trigger a change in its gene expression program. These signals can include transcription factor activation, epigenetic modifications, or environmental cues such as injury or stress. For example, in the liver, cholangiocytes can transdifferentiate into hepatocytes in response to injury, a process controlled by transcriptomic and epigenetic changes. Similarly, smooth muscle cells in atherosclerosis can transdifferentiate into macrophage-like cells in response to lipid accumulation and inflammatory signals.
Transcriptional and Epigenetic Remodeling
In simple terms: The cell rewrites its instruction manual by turning genes on and off and modifying how DNA is packaged.
The core of transdifferentiation involves extensive transcriptional and epigenetic remodeling. Key transcription factors that define the original cell fate are downregulated, while factors specifying the new fate are activated. Epigenetic changes, including DNA methylation and histone modifications, facilitate the silencing of old identity genes and the activation of new ones. For instance, cholangiocyte-to-hepatocyte transdifferentiation involves dynamic changes in chromatin accessibility and histone marks that enable hepatocyte-specific gene expression.
Loss of Original Identity and Acquisition of New Identity
In simple terms: The cell gradually stops being what it was and starts becoming something else.
As transdifferentiation proceeds, the cell loses markers and functions of its original type and gains those of the new type. This is often accompanied by changes in cell morphology, metabolism, and proliferative capacity. In pancreatic beta cells, transdifferentiation into alpha or delta cells involves loss of insulin expression and gain of glucagon or somatostatin expression. In alveolar epithelium, type 2 cells can transdifferentiate into metaplastic KRT5+ basal cells, a process linked to lung injury and repair.
Stabilization of the New Cell Fate
In simple terms: The new cell type becomes stable and maintains its new identity.
Once transdifferentiation is complete, the new cell fate is stabilized through sustained expression of lineage-specific transcription factors and epigenetic modifications that lock in the new gene expression program. This stabilization ensures that the cell does not revert to its original type. For example, in skeletal development, transdifferentiation of chondrocytes into osteoblasts is stabilized by Runx2 and Osterix expression. The stability of the new fate is crucial for tissue function and is often maintained by autoregulatory loops and chromatin remodeling.
Key Genes Involved in GO:0060290 transdifferentiation
The following genes and proteins are key regulators or markers of transdifferentiation across various biological contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCN2 | Regulates smooth muscle cell transdifferentiation and lipid accumulation | Implicated in atherosclerosis; potential target for modulating plaque stability |
| KRT5 | Marker of metaplastic basal cells derived from alveolar type 2 cells | Used to identify transdifferentiated cells in lung injury models |
| RUNX2 | Master transcription factor for osteoblast differentiation | Key regulator of chondrocyte-to-osteoblast transdifferentiation in skeletal development |
| SOX9 | Transcription factor for chondrocyte identity | Downregulated during transdifferentiation to osteoblasts |
| PDX1 | Pancreatic beta-cell transcription factor | Loss of PDX1 is associated with beta-cell dedifferentiation and transdifferentiation |
| MAFA | Beta-cell maturation factor | Downregulation linked to beta-cell transdifferentiation in diabetes |
| FOXA2 | Endoderm transcription factor | Involved in cholangiocyte-to-hepatocyte transdifferentiation |
| HNF4A | Hepatocyte nuclear factor | Upregulated during cholangiocyte-to-hepatocyte conversion |
| TWIST1 | Epithelial-mesenchymal transition regulator | Can promote transdifferentiation in cancer and fibrosis |
| SNAI1 | Induces epithelial-mesenchymal transition | Potential driver of transdifferentiation in glioblastoma |
| MYOD1 | Master regulator of myogenesis | Can induce transdifferentiation of fibroblasts into myoblasts |
| ASCL1 | Neuronal transcription factor | Induces transdifferentiation of glial cells into neurons |
| GATA4 | Cardiac transcription factor | Can promote transdifferentiation of fibroblasts into cardiomyocytes |
| CEBPA | Myeloid transcription factor | Induces transdifferentiation of lymphoid cells into macrophages |
| PPARG | Adipogenic transcription factor | Can drive transdifferentiation of myoblasts into adipocytes |
| MITF | Melanocyte master regulator | Induces transdifferentiation of neural crest cells into melanocytes |
| NEUROG3 | Neurogenin 3, endocrine progenitor factor | Involved in pancreatic endocrine cell transdifferentiation |
| HNF1B | Transcription factor for liver and pancreas | Mutations linked to cholangiocyte transdifferentiation defects |
How Is transdifferentiation Regulated?
Transdifferentiation is regulated at multiple levels, including transcriptional, epigenetic, and signaling pathways. Key signaling pathways such as TGF-beta, Wnt, and Notch can influence cell fate conversion. For example, TGF-beta signaling promotes smooth muscle cell transdifferentiation in atherosclerosis. Epigenetic regulators, including DNA methyltransferases and histone deacetylases, modulate the accessibility of lineage-specific genes. In pancreatic beta cells, the transcription factor PDX1 and its downstream targets are critical for maintaining beta-cell identity, and their downregulation leads to transdifferentiation. Additionally, microRNAs and long non-coding RNAs can fine-tune transdifferentiation processes. The balance between pro-transdifferentiation and anti-transdifferentiation factors determines whether a cell undergoes fate conversion.
transdifferentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCN2 | Atherosclerosis | Smooth muscle cell-specific knockout or overexpression in ApoE-/- mice |
| PDX1 | Type 2 diabetes | Beta-cell-specific knockout or inducible overexpression in mice |
| FOXA2 | Liver disease | Cholangiocyte-specific knockout or knock-in in zebrafish or mice |
| KRT5 | Pulmonary fibrosis / lung cancer | Alveolar type 2 cell-specific lineage tracing in mice |
| TWIST1 | Glioblastoma | Cancer stem cell knockout or overexpression in xenograft models |
Transdifferentiation in Atherosclerosis
In atherosclerosis, vascular smooth muscle cells can transdifferentiate into macrophage-like cells, contributing to plaque formation and instability. CCN2 (cellular communication network factor 2) regulates this process and lipid accumulation, making it a potential therapeutic target. This transdifferentiation is driven by inflammatory signals and lipid overload, and understanding its mechanisms could lead to new treatments for cardiovascular disease.
Transdifferentiation in Diabetes
Pancreatic beta-cell dedifferentiation and transdifferentiation into other endocrine cell types contribute to beta-cell failure in type 2 diabetes. Loss of key beta-cell transcription factors such as PDX1 and MAFA is associated with this process. Targeting these pathways could preserve beta-cell function or promote regeneration.
Transdifferentiation in Liver Disease
Cholangiocytes can transdifferentiate into hepatocytes in response to liver injury, a process controlled by transcriptomic and epigenetic mechanisms. This transdifferentiation can contribute to liver regeneration but may also be involved in pathological conditions such as cholangiocarcinoma.
Transdifferentiation in Cancer
Cancer stem cells can undergo transdifferentiation, contributing to tumor heterogeneity and therapy resistance. In glioblastoma, graphene-induced transdifferentiation of cancer stem cells has been explored as a therapeutic strategy. Similarly, alveolar type 2 cells transdifferentiate into metaplastic KRT5+ basal cells in lung injury, a process that may predispose to lung cancer.
From transdifferentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is gene X required for transdifferentiation? | CRISPR knockout in primary cells or cell lines, followed by transdifferentiation induction |
| Does a specific point mutation in gene X affect transdifferentiation? | CRISPR point mutation knock-in (e.g., HDR) in cell lines |
| Can gene X overexpression induce transdifferentiation? | CRISPR activation (CRISPRa) or lentiviral overexpression |
| What is the epigenetic landscape during transdifferentiation? | CRISPR knockout of epigenetic modifiers combined with ATAC-seq and ChIP-seq |
| Can small molecules replace transcription factors for transdifferentiation? | Chemical screening with CRISPR knockout libraries |
| How does gene X contribute to disease-associated transdifferentiation? | Conditional knockout in mouse disease models (e.g., atherosclerosis, diabetes) |
How to Study the transdifferentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identifying transcriptional programs during transdifferentiation |
| ATAC-seq | Chromatin accessibility | Mapping regulatory elements that change during fate conversion |
| ChIP-seq | Histone modifications and transcription factor binding | Studying epigenetic remodeling |
| Proteomics | Protein abundance and modifications | Validating transcriptomic findings and discovering new players |
| Lineage tracing | Cell fate conversion in vivo | Tracking transdifferentiation in animal models |
| Immunofluorescence | Protein expression and localization | Confirming loss of old markers and gain of new markers |
| Single-cell RNA-seq | Heterogeneity and intermediate states | Dissecting transdifferentiation trajectories |
| CRISPR screening | Gene function in transdifferentiation | Identifying essential regulators |
Transcriptomic Analysis
RNA sequencing (RNA-seq) is widely used to profile gene expression changes during transdifferentiation. It can identify upregulated and downregulated genes, alternative splicing events, and novel transcripts. For example, RNA-seq of cholangiocytes undergoing transdifferentiation into hepatocytes revealed dynamic changes in hepatocyte-specific genes. Single-cell RNA-seq can capture heterogeneity and intermediate states.
Epigenomic Profiling
Assays such as ATAC-seq, ChIP-seq for histone modifications, and whole-genome bisulfite sequencing are used to study epigenetic changes during transdifferentiation. These methods reveal changes in chromatin accessibility, histone marks, and DNA methylation that accompany cell fate conversion. For instance, ATAC-seq has been used to identify regulatory elements that become accessible during cholangiocyte-to-hepatocyte transdifferentiation.
Proteomic and Metabolomic Approaches
Mass spectrometry-based proteomics and metabolomics can quantify protein and metabolite changes during transdifferentiation. These methods complement transcriptomic data and provide insights into functional changes. For example, proteomics has been used to study smooth muscle cell transdifferentiation in atherosclerosis.
Imaging and Lineage Tracing
Live-cell imaging and lineage tracing using fluorescent reporters allow visualization of transdifferentiation in real time. In mouse models, Cre-loxP systems can permanently label cells of one type and track their conversion to another. Immunofluorescence for lineage-specific markers confirms the new cell identity.
How CRISPR Can Be Used to Study GO:0060290 transdifferentiation
Knockout
CRISPR knockout (KO) is used to test the requirement of a gene for transdifferentiation. By disrupting a candidate gene, researchers can assess whether transdifferentiation is impaired or enhanced. For example, knocking out CCN2 in smooth muscle cells can reveal its role in transdifferentiation and lipid accumulation in atherosclerosis. KO models are also valuable for studying epigenetic modifiers and transcription factors.
Point Mutation
CRISPR point mutation knock-in allows the introduction of specific disease-associated or functional mutations into a gene. This is useful for studying how subtle genetic changes affect transdifferentiation. For instance, point mutations in PDX1 that impair its function can be modeled to understand beta-cell transdifferentiation in diabetes. Point mutations can also be used to dissect phosphorylation sites or DNA-binding residues.
Knock-in
CRISPR knock-in can be used to insert reporter genes (e.g., fluorescent proteins) or tags into endogenous loci to track transdifferentiation. For example, knocking in a GFP reporter into the KRT5 locus allows visualization of alveolar type 2 cell transdifferentiation into KRT5+ basal cells. Knock-in of lineage-specific promoters driving Cre recombinase enables lineage tracing.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression via lentiviral vectors can drive ectopic expression of transcription factors to induce transdifferentiation. For example, overexpression of MYOD1 can convert fibroblasts into myoblasts. Overexpression of ASCL1 can induce neuronal transdifferentiation. These approaches are powerful for identifying minimal sets of factors sufficient for fate conversion.
How EDITGENE Supports transdifferentiation Research
Researchers studying transdifferentiation-related genes often need to determine whether a candidate gene is causally involved in cell fate conversion or is merely a bystander. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides comprehensive services to support such studies, from custom cell line generation to high-throughput screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for transdifferentiation research.
Frequently Asked Questions About transdifferentiation
What is transdifferentiation?
Transdifferentiation is the conversion of a differentiated cell of one type into a differentiated cell of another type without undergoing cell division or reverting to a stem-cell-like state.
What is GO:0060290?
GO:0060290 is the Gene Ontology identifier for the biological process of transdifferentiation.
What genes are involved in transdifferentiation?
Key genes include CCN2, KRT5, RUNX2, SOX9, PDX1, MAFA, FOXA2, HNF4A, TWIST1, and others, depending on the cell types involved.
How is transdifferentiation different from dedifferentiation?
Dedifferentiation is the reversion of a differentiated cell to a less differentiated state, while transdifferentiation is a direct conversion to another differentiated cell type without an intermediate stem-cell-like state.
Can transdifferentiation be induced artificially?
Yes, transdifferentiation can be induced by overexpression of transcription factors or by small molecules, as demonstrated in chemical reprogramming studies.
What diseases involve transdifferentiation?
Transdifferentiation is implicated in atherosclerosis, diabetes, liver disease, glioblastoma, and pulmonary fibrosis, among others.
How do researchers study transdifferentiation?
Researchers use RNA-seq, ATAC-seq, ChIP-seq, proteomics, lineage tracing, and CRISPR-based genetic manipulation to study transdifferentiation.
What is the role of CCN2 in transdifferentiation?
CCN2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis.
Can CRISPR be used to study transdifferentiation?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are widely used to test gene function in transdifferentiation.
What are the therapeutic implications of transdifferentiation?
Transdifferentiation offers potential for regenerative medicine, such as converting fibroblasts into cardiomyocytes or hepatocytes, and for targeting pathological cell fate changes in cancer and fibrosis.
Conclusion
Transdifferentiation (GO:0060290) is a fundamental biological process that enables direct cell fate conversion without dedifferentiation. It plays critical roles in development, tissue regeneration, and disease, and is regulated by complex transcriptional and epigenetic networks. Understanding its mechanisms offers opportunities for therapeutic intervention in conditions such as diabetes, atherosclerosis, and cancer. CRISPR-based models are indispensable for dissecting the genetic control of transdifferentiation, and EDITGENE provides comprehensive services to support such research.
References
- 1. Xu Q et al.. 2024. Cellular communication network factor 2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis.. Cardiovasc Res 120(17):2191-2207 PMID: 39365752
- 2. Zhang Y et al.. 2023. Chemical Transdifferentiation of Somatic Cells: Unleashing the Power of Small Molecules.. Biomedicines 11(11) PMID: 38001913
- 3. Galanakis V et al.. 2026. Transcriptomic and epigenetic mechanisms controlling cholangiocyte transdifferentiation into hepatocytes.. J Hepatol 84(3):618-630 PMID: 41033615
- 4. Martelli C et al.. 2020. Graphene-Induced Transdifferentiation of Cancer Stem Cells as a Therapeutic Strategy against Glioblastoma.. ACS Biomater Sci Eng 6(6):3258-3269 PMID: 33463176
- 5. Wang W et al.. 2021. Targeting β-cell dedifferentiation and transdifferentiation: opportunities and challenges.. Endocr Connect 10(8):R213-R228 PMID: 34289444
- 6. Wang K et al.. 2022. The Emerging Role of Cell Transdifferentiation in Skeletal Development and Diseases.. Int J Mol Sci 23(11) PMID: 35682655
- 7. Thowfeequ S et al.. 2007. Transdifferentiation in developmental biology, disease, and in therapy.. Dev Dyn 236(12):3208-17 PMID: 17948254
- 8. Kathiriya JJ et al.. 2022. Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5(+) basal cells.. Nat Cell Biol 24(1):10-23 PMID: 34969962
